1. De Souza NJ, Deshpande PK, Shukla MC, Mukaram SMJ, Kulkarni DG, Ansari AR, Yeole RD, Patel MV, Gupte SV (2003) Crystalline fluoroquinolone arginine salt form. Google Patents (US Patent No, US6664267B1)
2. De Souza NJ, Gupte SV, Deshpande PK, Desai VN, Bhavsar SS, Yeole RD (2005) A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. J Med Chem 48:5232–5242. https://doi.org/10.1021/jm050035f
3. Appelbaum PC, Pankuch GA, Bozdogan B, Lin G, Jacobs MR, Patel MV, Gupte SV, Jafri MA, De Sourza NJ, Khorakiwala HF (2004) Activity of the new quinolone WCK 771 against pneumococci. Clin Micro Infect Dis 11:9–14. https://doi.org/10.1111/j.1469-0691.2004.01017.x
4. Flamm RK, Farrell DJ, Sader HS, Rhomberg PR, Jones RN (2016) In vitro activity of WCK 771, a benzoquinolizine fluoroquinolone (Levonadifloxacin) when tested against contemporary Gram-positive and negative bacteria from a global surveillance program. Abstract Sunday-456. ASM Microbe, Boston, MA. American Society for Microbiology, Washington
5. Bhagwat S, Nandanwar M, Kansagara A, Patel A, Takalkar S, Chavan R, Periasamy H, Yeole R, Deshapane PK, Bhavsar S, Bhatia A, Ahdal J, Jain R, Patel M (2019) Levonadifloxacin, a novel broad-spectrum anti-MRSA benzoquinolizine quinolone agent: review of current evidence. Drug Des Dev Ther 13:1351–1365. https://doi.org/10.2147/DDDT.S229882